Article
Overexpression of wildtype EGFR is tumorigenic and denotes a therapeutic target in non-small cell lung cancer.
Oncotarget - 26 Jan 2016
Xu Naiqing, Fang Wenfeng, Mu Libing, Tang Yanna, Gao Lei, Ren Shengxiang, Cao Dengfeng, Zhou Lixin, Zhang Aiqun, Liu Deruo, Zhou Caicun, Wong Kwok-Kin, Yu Lei, Zhang Li, Chen Liang
Abstract excerpt
Current guidelines for lung cancer treatment with EGFR tyrosine kinase inhibitors (TKI) include only patients with mutated EGFR, although some patients with wildtype EGFR (wt-EGFR) have exhibited positive responses to this therapy as well. Biomarkers predicting the benefit from EGFR-TKIs treatment remain to be determined for patients with wild-type EGFR.Here, we report that wt-EGFR overexpression transformed...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.